AU2002319867A1 - Streptococcus agalactiae genome sequence, use for developing vaccines, diagnostic tools, and for identifying therapeutic targets - Google Patents

Streptococcus agalactiae genome sequence, use for developing vaccines, diagnostic tools, and for identifying therapeutic targets

Info

Publication number
AU2002319867A1
AU2002319867A1 AU2002319867A AU2002319867A AU2002319867A1 AU 2002319867 A1 AU2002319867 A1 AU 2002319867A1 AU 2002319867 A AU2002319867 A AU 2002319867A AU 2002319867 A AU2002319867 A AU 2002319867A AU 2002319867 A1 AU2002319867 A1 AU 2002319867A1
Authority
AU
Australia
Prior art keywords
genome sequence
therapeutic targets
streptococcus agalactiae
diagnostic tools
identifying therapeutic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002319867A
Other languages
English (en)
Inventor
Carmen Buchrieser
Fabien Chevalier
Elisabeth Couve
Lionel Frangeul
Philippe Glaser
Frank Kunst
Lila Lalioui
Claire Poyart
Christophe Rusniok
Patrick Trieu-Cuot
Mohamed Zouine
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Institut Pasteur de Lille
Original Assignee
Centre National de la Recherche Scientifique CNRS
Institut Pasteur de Lille
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique CNRS, Institut Pasteur de Lille filed Critical Centre National de la Recherche Scientifique CNRS
Publication of AU2002319867A1 publication Critical patent/AU2002319867A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AU2002319867A 2001-04-26 2002-04-26 Streptococcus agalactiae genome sequence, use for developing vaccines, diagnostic tools, and for identifying therapeutic targets Abandoned AU2002319867A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0105642A FR2824074A1 (fr) 2001-04-26 2001-04-26 Sequence du genome streptococcus agalactiae, application au developpement de vaccins, d'outils de diagnostic, et a l'identification de cibles therapeutiques
FR2001/05642 2001-04-26
PCT/IB2002/003059 WO2002092818A2 (fr) 2001-04-26 2002-04-26 Sequence du genome streptococcus agalactiae et ses utilisations

Publications (1)

Publication Number Publication Date
AU2002319867A1 true AU2002319867A1 (en) 2002-11-25

Family

ID=8862732

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002319867A Abandoned AU2002319867A1 (en) 2001-04-26 2002-04-26 Streptococcus agalactiae genome sequence, use for developing vaccines, diagnostic tools, and for identifying therapeutic targets

Country Status (3)

Country Link
AU (1) AU2002319867A1 (fr)
FR (1) FR2824074A1 (fr)
WO (1) WO2002092818A2 (fr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6890539B2 (en) 1998-12-22 2005-05-10 Microscience, Ltd. Genes and proteins, and their use
EP1328543B1 (fr) 2000-10-27 2009-08-12 Novartis Vaccines and Diagnostics S.r.l. Acides nucleiques et proteines derives des groupes de streptocoques a et b
US7691571B2 (en) 2001-01-31 2010-04-06 Mayo Foundation For Medical Education And Research Detection of bordetella
ES2338637T3 (es) 2001-02-21 2010-05-11 Id Biomedical Corporation Polipeptidos de streptococcus pyogenes y fragmentos de adn correspondiente.
DE60234772D1 (de) 2001-07-06 2010-01-28 Id Biomedical Corp Gruppe-b streptococcus antigene und entsprechende dna-fragmente
GB0210128D0 (en) * 2002-05-02 2002-06-12 Chiron Spa Nucleic acids and proteins from streptococcus groups A & B
BR0313237A (pt) * 2002-08-12 2005-07-12 Akzo Nobel Nv Sequência de ácido nucleico, fragmento de dna, molécula de dna recombinante, veìculo recombinante vivo, célula hospedeira, proteìna de streptococcus uberis, usos da mesma e de uma sequência de ácido nucleico, de um fragmento de dna, de uma molécula de dna recombinante, de um veìculo recombinante vivo, de uma célula hospedeira ou de uma proteìna ou de um fragmento imunogênico da mesma, vacina, método para a preparação da mesma, e, kit diagnóstico
US7074598B2 (en) 2002-09-25 2006-07-11 Mayo Foundation For Medical Education And Research Detection of vancomycin-resistant enterococcus spp.
US7365176B2 (en) 2002-09-26 2008-04-29 Mayo Foundation For Medical Education And Research Detection of Epstein-Barr virus
JP5116971B2 (ja) * 2002-10-15 2013-01-09 インターセル アーゲー Ｂ群連鎖球菌の接着因子をコードする核酸、ｂ群連鎖球菌の接着因子、およびその使用
WO2004078907A2 (fr) * 2003-03-04 2004-09-16 Intercell Ag Antigenes vis-a-vis du streptococcus pyogenes
EP2333114A1 (fr) 2003-04-15 2011-06-15 Intercell AG S. pneumoniae antigènes
JP2007535894A (ja) * 2003-05-07 2007-12-13 インターツェル・アクチェンゲゼルシャフト ストレプトコッカス・アガラクティエ抗原ｉ＋ｉｉ
PL1648500T3 (pl) 2003-07-31 2014-12-31 Novartis Vaccines & Diagnostics Inc Kompozycje immunogenne dla Streptococcus pyogenes
US8945589B2 (en) 2003-09-15 2015-02-03 Novartis Vaccines And Diagnostics, Srl Immunogenic compositions for Streptococcus agalactiae
CA2537742C (fr) * 2003-09-15 2014-07-22 Chiron Corporation Compositions immunogenes pour streptococcus agalactiae
WO2005052145A2 (fr) * 2003-10-07 2005-06-09 University Of Florida Bacteries alcalinisantes de recombinaison
US7427475B2 (en) 2003-11-18 2008-09-23 Mayo Foundation For Medical Education And Research Detection of group B streptococcus
US20090317420A1 (en) * 2004-07-29 2009-12-24 Chiron Corporation Immunogenic compositions for gram positive bacteria such as streptococcus agalactiae
MX2007007033A (es) * 2004-12-22 2007-08-03 Novartis Vaccines & Diagnostic Estreptococus del grupo b.
US20060177859A1 (en) 2005-02-07 2006-08-10 Gen-Probe Incorporated Compositions and methods for detecting group B streptococci
WO2006130328A2 (fr) 2005-05-13 2006-12-07 Novartis Vaccines And Diagnostics, Inc. Facteurs de resistance au serum de bacteries a gram positif
US20100261618A1 (en) * 2006-06-19 2010-10-14 Sonia Escaich Identification of genes implicated in the virulence of streptococcus agalactiae
EP2059531A1 (fr) 2006-07-07 2009-05-20 Intercell AG Petits antigènes de streptococcus pyogenes et leur utilisation
RU2471497C2 (ru) 2007-09-12 2013-01-10 Новартис Аг Мутантные антигены gas57 и антитела против gas57
US9175353B2 (en) 2008-11-14 2015-11-03 Gen-Probe Incorporated Compositions, kits and methods for detection of campylobacter nucleic acid
US8877909B2 (en) 2011-04-04 2014-11-04 Intelligent Medical Devices, Inc. Optimized oligonucleotides and methods of using same for the detection, isolation, amplification, quantitation, monitoring, screening, and sequencing of group B Streptococcus
EP2557424A1 (fr) * 2011-08-11 2013-02-13 InGen Biosciences Procédé pour le diagnostic d'infections par les genres Streptococcus, Enterococcus et Pepstostreptococcus
CN104321335A (zh) * 2012-02-24 2015-01-28 诺华股份有限公司 菌毛蛋白质和组合物
KR102704583B1 (ko) 2016-02-04 2024-09-06 게노비스 에이비 신규한 스트렙토코커스 프로테아제
PL239045B1 (pl) * 2018-01-09 2021-11-02 Inst Immunologii I Terapii Doswiadczalnej Polskiej Akademii Nauk Epitop specyficzny dla zakaźnych Streptococcus agalactiae oraz sposób wykrywania zakażenia pacjenta szczepem Streptococcus agalactiae

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2540281T3 (es) * 1998-02-20 2015-07-09 Id Biomedical Corporation Of Quebec Antígenos de estreptococos del grupo B
JP4749641B2 (ja) * 1999-08-25 2011-08-17 メディミューン，エルエルシー ワクチン用の肺炎球菌タンパク質の相同体および断片

Also Published As

Publication number Publication date
WO2002092818A8 (fr) 2004-03-04
WO2002092818A3 (fr) 2003-08-28
FR2824074A1 (fr) 2002-10-31
WO2002092818A2 (fr) 2002-11-21

Similar Documents

Publication Publication Date Title
AU2002319867A1 (en) Streptococcus agalactiae genome sequence, use for developing vaccines, diagnostic tools, and for identifying therapeutic targets
AU2002363253A1 (en) Endothelial-cell binding peptides for diagnosis and therapy
AU2002352799A1 (en) Methods for evaluating drug-resistance gene expression in the cancer patient
AU2002311909A1 (en) Compositions and methods for the therapy and diagnosis of lung cancer
AU2002303219A1 (en) Compositions and methods for the therapy and diagnosis of cancer
AU2002359330A1 (en) Compositions and methods for the therapy and diagnosis of lung cancer
AU2002258728A1 (en) Gene brcc-3 and diagnostic and therapeutic uses thereof
AU2002305151A1 (en) Gene scc-112 and diagnostic and therapeutic uses thereof
AU2002303261A1 (en) Gene brcc2 and diagnostic and therapeutic uses thereof
AU2002342053A1 (en) Pancreatic cancer diagnosis and therapies
AU2003289603A1 (en) Tumor vaccine
AU2001259062A1 (en) Compositions and methods for the therapy and diagnosis of lung cancer
MXPA03006249A (es) Derivados de 2-arilimino-2,3-dihidrotiazoles, sus procesos de preparacion y su uso terapeutico.
AU2002256053A1 (en) Novel bgp compounds for therapy and diagnosis and methods for using same
AU2002335667A1 (en) Modified reoviral therapy
AU2002320230A1 (en) Distal anastomosis system
AU2001273127A1 (en) Compositions and methods for the therapy and diagnosis of lung cancer
AUPS084502A0 (en) Anti-protozoal vaccine
AU2002232563A1 (en) Compounds for therapy and diagnosis and methods for using same
AU2002322013A1 (en) Therapeutic dna vaccination
AU2002347346A1 (en) Dna vaccine
AU2002315309A1 (en) Vaccine against tuberculosis
AU2001274973A1 (en) Compositions and methods for the therapy and diagnosis of lung cancer
AU2002256054A1 (en) Novel eps8 compounds for therapy and diagnosis and methods for using same
AU2002367463A1 (en) NOVEL p53BP2 COMPOUNDS FOR THERAPY AND DIAGNOSIS AND METHODS FOR USING SAME

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase